Non-proliferative Diabetic Retinopathy Treated With Runcaciguat

• Status: Recruiting
• Trial end date: 2026-01-27
• Target enrollment: 0
• Participant gender: All

Summary

This Phase 2 study is conducted to investigate the safety and efficacy of runcaciguat in the treatment of diabetic retinopathy. The study consists of two parts, Part A and Part B. Part A is designed to assess the safety and efficacy of runcaciguat in NPDR patients. Part B is designed to investigate the dose-response of runcaciguat in the treatment of diabetic retinopathy and to determine the dose with the best benefit/risk ratio. To assess efficacy, the retinal morphology will be investigated by 7-field color fundus photography for central assessment of the diabetic retinopathy severity score, or DRSS. Two-step DRSS improvement at 24 weeks of treatment will be the primary efficacy endpoint. DRSS assessments are repeated after completion of 48, 72, and 96 weeks of treatment. In addition, vision threatening complications will be recorded throughout the study and assessed as secondary efficacy endpoint.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bayer

Criteria

Main Inclusion Criteria:

• Moderately severe to severe NPDR in the study eye: Diabetic Retinopathy Severity Scale (DRSS) levels 47 or 53

• Diabetes type 1 or 2

• Best corrected visual acuity (BCVA) Early Treatment Diabetic Retinopathy Study (ETDRS) letter score in the study eye of ≥69 letters (approximate Snellen equivalent of 20/40 or better)

Main Exclusion Criteria:

• Presence or history of macular edema involving the center of the macula

• Any kind of neovascular growth in the study eye, including anterior segment neovascularization

• Arterial hypotension with systolic blood pressure < 100 or diastolic blood pressure < 60mmHg

• Alanine aminotransferase (ALT) or Aspartate aminotransferase (AST) above 3 x Upper limit of normal (ULN) or bilirubin ≥ 1.5 ULN at screening, known ascites

• Estimated glomerular filtration rate (eGFR CKD-EPI) below 45 ml/min/1.73 m^2 at screening

• Any prior systemic anti-Vascular endothelial growth factor (VEGF) treatment or IVT anti-VEGF treatment in the study eye

• Any prior intraocular steroid injection in the study eye

• Any prior grid or focal laser photocoagulation within 500 microns of the foveal center or any prior Pan-retinal photocoagulation (PRP) in the study eye

• Use of nitrates or Nitric oxide (NO) donors (such as amyl nitrate) in any form including topical; Phosphodiesterase 5 (PDE5) inhibitors, nonspecific PDE inhibitors within 1 week or less than 5 half-lives (whichever is longer) before first study drug administration